Form 4: Solen Therapeutics CFO Sells Shares to Cover Tax Obligations

Solen Therapeutics' Chief Financial Officer, James Mackaness, sold a portion of his shares to cover tax obligations related to vesting restricted stock units.

Summary

• James Mackaness, the Chief Financial Officer of Soleno Therapeutics, sold shares of common stock on January 2nd and 3rd, 2025.
• The sales were made to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs).
• On January 2nd, 2025, Mr. Mackaness sold 3,762 shares at a weighted average price of $45.3656 and 321 shares at a weighted average price of $45.92.
• On January 3rd, 2025, he sold 3,791 shares at a weighted average price of $46.1764.
• Following these transactions, Mr. Mackaness beneficially owns 111,298 shares of common stock, some of which are RSUs.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction for tax purposes, not indicative of any positive or negative sentiment towards the company's performance.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax obligations when RSUs vest.

Comparison to Industry Standards

• Executive stock sales to cover tax obligations are a common practice across the industry.
• The sale prices are within the typical range for stock transactions of this nature.
• The volume of shares sold is not unusual for an executive managing their personal finances.

Stakeholder Impact

• The stock sales may have a minor impact on the stock price, but are not expected to significantly affect shareholders.

Key Dates

Keywords

insider trading, stock sale, restricted stock units, tax obligations, Form 4, Solen Therapeutics, SLNO, James Mackaness